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Abstract
Glucose concentration may be an important factor in breast cancer cell proliferation, and the prevalence of breast cancer is high in diabetic
patients. Leptin may also be an important factor since plasma levels of leptin correlated with TNM staging for breast cancer patients. The
effects of glucose and leptin on breast cancer cell proliferation were evaluated by examining cell doubling time, DNA synthesis, levels of cell
cycle related proteins, protein kinase C (PKC) isozyme expression, and peroxisome proliferator-activated receptor (PPAR) subtypes were
determined following glucose exposure at normal (5.5 mM) and high (25 mM) concentrations with/without leptin in MCF-7 human breast
cancer cells. In MCF-7 cells, leptin and high glucose stimulated cell proliferation as demonstrated by the increases in DNA synthesis and
expression of cdk2 and cyclin D1. PKC-a, PPARg, and PPARa protein levels were up-regulated following leptin and high glucose treatment
in drug-sensitive MCF-7 cells. However, there was no significant effect of leptin and high glucose on cell proliferation, DNA synthesis,
levels of cell cycle proteins, PKC isozymes, or PPAR subtypes in multidrug-resistant human breast cancer NCI/ADR-RES cells. These results
suggested that hyperglycemia and hyperleptinemia increase breast cancer cell proliferation through accelerated cell cycle progression with
up-regulation of cdk2 and cyclin D1 levels. This suggests the involvement of PKC-a, PPARa, and PPARg.
D 2002 Elsevier Science B.V. All rights reserved.
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1. Introduction
Plasma leptin concentrations may be an important factor
in breast cancer cell proliferation. Because it has been
reported that a strong and statistically significant inverse
association of leptin levels with breast cancer prevalence in
premenopausal women [1] and plasma leptin levels correlate
with TNM staging [2]. Leptin is a 16 kDa protein encoded
by the ob gene and is secreted from adipocytes [3].
Although the putative role of leptin appears to control
satiety by providing information to the central nervous
system, the function of leptin was demonstrated to be more
complex [4–6] and its role has not been fully elucidated in
various cell functions. Since epidemiological studies reveal
that obesity has profound effects on breast cancer risk [7,8],
leptin could be a plausible factor contributing to the patho-
genesis of breast cancer. Furthermore, a recent report
suggests the possible use of plasma leptin levels as a clinical
marker of breast cancer [2]. Although leptin expression in
breast tumors has been demonstrated [9], its role in breast
cancer cell proliferation is not well understood.
Glucose concentrations may also be an important factor
in breast cancer cell proliferation because the prevalence of
breast cancer is high in diabetic patients [10–13]. We
reported that MCF-7 human breast cancer cell proliferation
was increased when glucose concentration in the culture
medium was increased [14].
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Cyclin-dependent kinases (cdks) are enzymes responsi-
ble for the coordinated progression of the cell cycle [15]. Of
nine cdks, cdk2 is involved in the control of cell cycle
progression from G1 to S phase. Cdks are activated by
association with D-type cyclins (cyclin D1, D2, and D3),
and cyclin D1 has an important role in G1 phase of cell
cycle progression in association with cdk2 [16]. Cyclin D1
is a rate-limiting activator of G1-to-S phase transition
[17,18], since changes in cyclin D1 and cdk2 expression
might reflect G1-to-S phase transition rate. Hence, we
examined cyclin D1 and cdk2 expression following glucose
exposure to demonstrate G1-to-S phase transition. In MCF-
7 cells, tumor necrosis factor-a (TNF-a) has anti-mitogenic
activity in early G1 phase as reflected by a decreased
number of cells in S phase [19]. Therefore, we treated
MCF-7 cells with TNF-a as a negative control of G1-to-S
phase transition in the process of cell proliferation.
Protein kinase C (PKC) is a complex family of at least 11
isozymes classified into three groups: classical PKCs
(cPKC) (PKC-a, -hI, -hII, and -g), which require diacyl-
glycerol (DAG), phospholipids and Ca2 + for full activity;
novel PKCs (nPKC) (PKC-y, -q, -D, and -u), which are
phospholipid and DAG-dependent but Ca2 + -independent;
and atypical PKCs (aPKC) (PKC-~ , -(L)E, and -A), which
require only phospholipids [20–22]. There is significant but
indirect evidence to suggest that one or more of the
individual PKC isozymes may play a major role in cell
growth and differentiation [23]. Alterations in the intra-
cellular concentration of certain PKC isozymes induce cell
differentiation [24]. In addition, we have demonstrated that
high glucose-induced decreases of PKC-hII protein and
mRNA levels might be important in response to high
glucose levels [14]. Cellular PKC-hII levels may have to
fall below a threshold for stimulation of cell proliferation. In
some cells, glucose-induced decrease in PKC-hII level may
not fall below this threshold for stimulation of cell prolif-
eration. This can explain the differences in the proliferative
response of different cells to high glucose medium. PKC
isozymes may have various roles in the regulation of breast
cancer cell proliferation, however, the relationship between
PKC function and regulation of cell proliferation has not
been fully elucidated. We studied the effects of high glucose
and leptin on expression of PKC-a, -u, and -~ , representing
cPKC, nPKC, and aPKC, families of isozymes, respectively.
Peroxisome proliferator-activated receptors (PPARs) are
nuclear hormone receptors that can be activated by a variety
of compounds such as thiazolidinediones and fatty acids
[25–28]. Three PPAR subtypes, designated PPARa, PPARh
and PPARg, have been described [25]. Although PPARg
has been reported to have a role in the breast cancer cell
differentiation [29], the precise functions of PPAR in
regulation of cell cycle related to control of cell proliferation
have not been studied. We examined the effect of high
glucose and leptin on expression of PPARa and g.
On the basis of epidemiological data and our previous
study [14], we now describe the effects of leptin and glucose
on MCF-7 human breast cancer cell proliferation, and the
expression of PKC isozymes and PPARs. Furthermore, we
examined the effects of high glucose and leptin on cell
proliferation and expression of PKC isozymes and PPARs
were evaluated in two unrelated cell lines, MCF-7 cells and
NCI/ADR-RES [30,31], in order to detect cell line related
difference to glucose and leptin.
2. Materials and methods
2.1. Cells and cell culture
Drug-sensitive MCF-7 human breast cancer cells and
multidrug-resistant NCI/ADR-RES human breast cancer
cells were obtained from Dr. P.B. Desai, University of
Cincinnati, College of Pharmacy, OH. Multidrug-resistant
NCI/ADR-RES cells were developed by Dr. K.H. Cowan of
NCI, Bethesda, MD. Both cell lines were passaged in RPMI
1640 media (Gibco-BRL, Gaithersburg, MD) supplemented
with 5% fetal bovine serum (FBS) (Gibco-BRL), 50 U/ml
penicillin G and 50 Ag/ml streptomycin sulfate, and 5.5 mM
glucose at 37 jC in a humidified, 5% CO2, 95% air
atmosphere. Cells were subcultured weekly to maintain
logarithmic growth in 6-well plates. NCI/ADR-RES was
passaged in drug-free media for at least eight passages before
testing. We compared the effects of leptin and glucose on
proliferation of MCF-7 and NCI/ADR-RES cells to identify
cell line-related differences. Although NCI/ADR-RES cells
were previously referred to as MCF-7/ADR cells, it must be
emphasized that they are not genetically related to, or derived
from MCF-7 human breast cancer cells [30,31].
2.2. Cell proliferation
Cells in secondary cultures were maintained in RPMI
1640 containing 5% FBS with 5.5 mM glucose. Cells were
trypsinized and seeded on 6-well plates (Costar, Cambridge,
MA) at 1104 cells/well in 3 ml of RPMI 1640 containing
5% FBS with 5.5 or 25 mM glucose. Leptin (Pepro Tech EC,
London, UK) and TNF-a (Pepro Tech EC) were added to
achieve a final concentration of 1 AM per well. Since TNF-a
suppressed cell proliferation through down-regulation of cell
cycle-related proteins in MCF-7 cells [19], we treated cells
with TNF-a as a negative control. To count cell number, cells
were washed with Dulbecco’s phosphate buffered saline
(DPBS) (Gibco-BRL), trypsinized for 3 min at 37 jC, and
centrifuged at 350 g for 5 min to remove trypsin. The cell
pellet was resuspended with DPBS containing 0.4% trypan
blue (Gibco-BRL) for viable cell counts with a haemacy-
tometer. Total viable cell counts were performed every day
without changing media for up to 6 days.
To examine the effect of leptin concentration on the
proliferation of cultured MCF-7 cells, cells were seeded at
approximately 1104 cells/well in 3 ml of RPMI 1640
containing 5% FBS with 5.5 mM glucose. MCF-7 cells were
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maintained in media in the absence or presence of varying
concentrations of leptin at 10 9 to 10 5 M per well. Total
viable cell counts were determined every day without chang-
ing media for up to 6 days using a different culture each day
from set of replicate cultures as described above.
2.3. DNA synthesis assay
DNA synthesis was determined by measuring the [3H]-
thymidine (dThd) incorporation into DNA of MCF-7 and
NCI/ADR-RES cells cultured in media containing 5.5 and
25 mM glucose. The effect of leptin and TNF-a on DNA
synthesis were also evaluated. Cultures were trypsinized and
seeded at approximately 1104 cells/well in 6-well plates
with 3 ml of the same medium. When cultures reached 80%
confluence, they were incubated with RPMI 1640 with 5.5
or 25 mM glucose containing 5% FBS for 72 h. Leptin and
TNF-a were added so that the final concentration of 1 AM
was achieved in each well for 24 h. Cells were then
incubated with 3 ml of the same media containing 1.0
ACi/ml [3H]dTd h (Du Pont-NEN, Boston, MA) for 1 h at
37 jC. After incubation, cells were washed twice with ice-
cold phosphate-buffered saline (0.15 M NaCl in 0.1 M
K2PO4 buffer, pH 7.4), acid-soluble radioactivity was
removed by a 20-min treatment with 5% trichloroacetic
acid (TCA), and washed twice with ethanol. Cells were
solubilized with 1 N NaOH and neutralized with 1 N HCl.
The [3H] radioactivity in the acid-soluble pools were deter-
mined by multipurpose scintillation counter LS6500 (Beck-
man Instruments, CA, USA). DNA synthesis was estimated
as cpm/ml per hour.
2.4. Western blot analysis
The changes in immunoreactive cdk2, cyclin D1, PKC
isozymes, and PPAR subtypes following 5.5 and 25 mM
glucose exposure with/without leptin or TNF-a were meas-
ured in MCF-7 and NCI/ADR-RES cells by Western blot
analysis. Cell cultures maintained in RPMI 1640 containing
5% FBS with 5.5 mM glucose were trypsinized and seeded
on 6-well plates at a density of 1106 cells/well in 3 ml of
the same medium. When cells were grown to 80% conflu-
ency, cells were incubated with serum-free RPMI 1640
media containing of 5.5 mM glucose for 72 h. Then, media
were switched to RPMI 1640 containing 5% FBS with 5.5
or 25 mM glucose and incubated with 1 AM of leptin or
TNF-a for 3 days. Subsequently, cells were washed with
ice-cold DPBS and scraped from dishes with a rubber
policeman. The cell suspension was centrifuged at 350 g
for 5 min to remove DPBS, and the cell pellet was lysed in a
buffer containing 20 mM Tris–HCl (pH 7.5), 145 mM
NaCl, 10% (w/v) glycerol, 5 mM EDTA, 0.2 mM Na2VO4,
0.1 mM phenylmethylsulfonylfluoride (PMSF) (Sigma), 10
Ag/ml leupeptin (Sigma), 10 Ag/ml aprotonin (Sigma), and
1% (w/v) nonyl phenoxy polyethoxy ethanol (NP-40)
(Sigma). The suspension was sonicated for 5 s, centrifuged
at 350 g for 5 min, and the resultant supernatant was used
as the whole-cell lysate fraction. The protein concentration
was determined by the method of Bradford [32] with bovine
serum albumin (BSA) as a standard using protein assay kit
(Bio-Rad, Hercules, CA). All procedures were performed at
4 jC. The same amount (25 Ag) of protein of each sample
was dissolved in Laemmli’s sample buffer containing 1%
SDS [33] and resolved by sodium dodecyl sulfate-poly-
acrylamide gel electrophoresis (SDS-PAGE) on 4.5% (w/v)
stacking gels and 10% (w/v) resolving gels in a RAPIDAS
mini slab (ATTO, Japan) and electrophoretically transferred
to nitrocellulose membranes Hybond-PR (Amersham LIFE
SCIENCE, Buckinghamshire, England). Membranes were
equilibrated in Tris-buffered saline (TBS; 20 mM Tris–HCl
and 500 mM NaCl, pH 7.40), and non-specific binding sites
were blocked by 5% dried milk in TBS containing 0.1%
Fig. 1. The effects of leptin and glucose on cell proliferation were examined in MCF-7 and NCI/ADR-RES cells. Cells were seeded in 6-well plates at
approximately 1104 cells/well in 3 ml of RPMI 1640 containing 5% FBS with normal (5.5 mM) or high (25 mM) glucose concentrations with/without leptin
or TNF-a. Total viable cell counts were determined daily using 0.4% trypan blue dye as described in Materials and methods. Data are the meansF S.D. for
triplicate determinations which were repeated in three separate experiments. *P < 0.05, * *P< 0.01 vs. control, n= 3.
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Tween-20 (TBS-T) at room temperature for 1–2 h. After
washing with TBS-T, membranes were incubated with in
TBS containing the rabbit polyclonal antibodies to cdk2,
cyclin D1, PKC-a, -u, and -~ , and PPARa and g (Santa
Cruz, CA) (dilution ratio 1:1000) as primary antibody at
room temperature for 3 h. After washing with TBS-T, the
membrane was incubated in TBS-T containing a goat anti-
rabbit g-globulin coupled to horseradish peroxidase (Bio-
Rad) (dilution ratio 1:1000) for 30 min. The blots were
developed with the enhanced chemiluminescense (ECL)
system (Amersham, Arlington Heights, IL), and visualized
by exposure to Hyperfilm-ECL (Amersham). Specificity of
protein bands was examined by blocking with antigens. The
developed films were analyzed by a densitometric scanner
linked to a Macintosh computer (Apple, Cupertino, CA).
2.5. Data analysis
Experiments were repeated separately at least three times
to assure reproducible results. Results are expressed as the
meansF standard deviation (S.D.) of the number of obser-
vations. The statistical significance was assessed by one-
way analysis of variance (ANOVA). A P-value < 0.05 was
considered statistically significant. Significance is deter-
mined after three or more separate experiments.
3. Results
3.1. Effect of leptin and glucose on MCF-7 cell proliferation
We examined MCF-7 and NCI/ADR-RES cell prolif-
eration at two concentrations of glucose reflecting normal
physiological glucose levels (5.5 mM) and hyperglycemic
levels (25 mM) with/without leptin or TNF-a. Maximum
MCF-7 and NCI/ADR-RES cell numbers were achieved
following 5 days of culture in 6-well plates. In Fig. 1,
MCF-7 and NCI/ADR-RES cell numbers on day 5 after
seeding is shown. In physiological glucose, MCF-7 cell
proliferation was increased compared to NCI/ADR-RES
cells. In MCF-7 cells, proliferation was stimulated sig-
nificantly by leptin exposure for 5 days with normal
glucose, and increased more significantly as MCF-7 were
grown in high glucose concentrations (Fig. 1). As
reported previously [19], cells grown with TNF-a sup-
pressed MCF-7 cell growth rate in normal and high
glucose conditions. We had previously demonstrated that
the osmotic control medium, 5.5 mM glucose with 19.5
mM mannitol, had no stimulatory effect on MCF-7 cell
proliferation [14]. On the contrary, there were no signifi-
cant differences in NCI/ADR-RES cell proliferation
among cultures grown in normal and in high glucose
concentration with leptin and TNF-a (Fig. 1).
We examined leptin-induced MCF-7 cell proliferation
by varying concentrations of leptin with normal physio-
logical glucose levels (5.5 mM) for 5 days. MCF-7 cell
proliferation increased as the level of leptin concentration
Fig. 2. Dose–response curve for leptin on MCF-7 cell proliferation. MCF-7
cells were maintained in the media for 5 days in various concentration of
leptin. Data are the meansF S.D. for triplicate determinations which were
repeated in three separate experiments. * *P < 0.01 vs. control, n= 3.
Fig. 3. DNA synthesis was determined by measuring [3H]-thymidine (dThd) incorporation into DNA in normal (5.5 mM) and high (25 mM) glucose with/
without leptin or TNF-a in MCF-7 and NCI/ADR-RES. Cells were seeded in 24-well plates and subjected to serum-deprivation for 72 h. The cell cycle was
initiated by switching to media containing serum, and [3H]-dThd incorporation was measured as described in Materials and methods. Data are the
meansF S.D. for triplicate determinations which were repeated in three separate experiments. *P < 0.05 vs. control (control), n= 3.
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increased and maximal proliferation was observed at 10 6
M (Fig. 2).
3.2. Stimulatory effects of high concentration of glucose and
leptin on [3H]-thymidine (dThd) incorporation in MCF-7
To further examine the effects of glucose and leptin on
cell proliferation, DNA synthesis was determined by dThd
incorporation following serum addition to initiate the cell
cycle in synchronized cells. In MCF-7 cells, the addition
of leptin caused an increase in dThd incorporation com-
pared with the control. TNF-a did not change dThd
incorporation regardless of glucose concentration (Fig.
3). However, leptin, glucose, and TNF-a had no signifi-
cant effect on dThd incorporation in NCI/ADR-RES cells
(Fig. 3).
To delineate whether leptin reduced cell death through
the regulation of apoptosis, we examined morphologic
changes by Hoechst 33258/propidium iodide (PI) stain-
ing, DNA fragmentation analysis, and cell death detection
Fig. 4. Cyclin D1 and cdk2 immunoreactivity following leptin treatment of MCF-7 and NCI/ADR-RES cells was investigated. Cells were grown in 6-well
plates, synchronized with serum-free media for 72 h, then the cell cycle was initiated by switching to media containing FBS with normal (5.5 mM) or high (25
mM) glucose concentrations and incubated with 1 AM of leptin or TNF-a over a 3-day period. After incubation, cyclin D1 and cdk2 immunoreactivity in whole
cell lysates was analyzed by Western blot using anti-cyclin D1- and cdk2-specific antibody (Santa Cruz) and analyzed by densitometric scanner as described in
Materials and methods. Data are shown as relative optical density (control level in MCF-7; 100%). Data are the meansF S.D. for triplicate determinations
which were repeated in three separate experiments. *P< 0.05 vs. control (control), n= 3.
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by ELISA assay in MCF-7 and NCI/ADR-RES cells.
However, there were no significant effects of leptin on
apoptosis or the expression of apoptotic markers such as
Bax, Bcl-2, or Bcl-XL (data not shown). Leptin induced
MCF-7 cell proliferation without altering apoptosis. Fur-
ther, leptin stimulated increase in dThd-incorporation into
cells indicating that the mitotic cycle is accelerated in
response to leptin.
3.3. Stimulatory effects of leptin and glucose on the
acceleration of cell cycle demonstrated by the expression
of cyclin D1 and cdk2 in MCF-7
Cdks and cyclin D1 are overexpressed as S phase
checkpoints in the cell cycle [15,16], in MCF-7 cells [19].
Therefore, we examined if changes in cdk2 and cyclin D1
protein expression occurred with leptin, high glucose, and
Fig. 5. PKC-a, -u and -~ immunoreactivity following leptin and high glucose treatment of MCF-7 and NCI/ADR-RES cells was investigated as described in
Materials and methods. Data are shown as relative optical density (control level in MCF-7; 100%) analyzed by densitometric scanner. Similar results were
obtained in three separate experiments. Data are the meansF S.D. for triplicate determinations which were repeated in three separate experiments. *P < 0.05
vs. control (control), n= 3.
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TNF-a treatment of MCF-7 and NCI/ADR-RES cells to
relate possible changes in G1-to-S transition in cell cycle
progression. Cyclin D1 and cdk2 protein levels increased
with leptin and high glucose treatment and decreased with
TNF-a treatment in MCF-7 cells, although these levels were
not changed in NCI/ADR-RES cells (Fig. 4). Leptin and
high glucose may have increased cell proliferation through
acceleration of cell cycle with up-regulation of cell cycle-
regulated proteins such as cyclin D1 and cdk2 in MCF-7
cells. However, in multidrug-resistant NCI/ADR-RES cells,
the checkpoint of cell cycle regulation may be altered
through modified functions of cell cycle-regulated proteins.
We used three methods to evaluate cell proliferation follow-
ing increases in glucose levels and leptin treatment. In Fig.
1, we demonstrated variable cell numbers following glucose
or leptin treatment for 5 days. In Fig. 3, DNA synthesis was
measured by [3H]-thymidine uptake for 1 h following
glucose or leptin treatment. In Fig. 4, we evaluated cell
cycle checkpoint protein expression to demonstrate cell
cycle progression after 72 h treatment of glucose or leptin
using Western blot analysis. When the methods are exam-
ined together, they present a cohesive description of glucose
and leptin effects in MCF-7 cells, despite modest variations
in their effect.
Fig. 6. PPARg and a immunoreactivity following leptin and high glucose treatment of MCF-7 and NCI/ADR-RES cells was investigated as described in
Materials and methods. Date are shown as relative optical density (control level in MCF-7; 100%) analyzed by densitometric scanner. Similar results were
obtained in three separate experiments. Data are the meansF S.D. for triplicate determinations which were repeated in three separate experiments. *P < 0.01
vs. control (control), n= 3.
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3.4. Effect of leptin and glucose on the expression of PKC-
a, -u and -~ in MCF-7
Leptin may have accelerated the cell cycle. To examine
if this was the case, we determined the expression of PKC-
a, -u, and -~ using Western blot analysis in MCF-7 and
NCI/ADR-RES treated with leptin in normal and high
glucose concentrations. Leptin increased PKC-a expression
in MCF-7 cells, and high glucose had an additive effect.
TNF-a appeared to suppress PKC-a expression during the
cell cycle, as shown in Fig. 5. No significant changes in
PKC-u and -~ protein levels were detected with high
glucose and leptin treatments, but PKC-u and -~ protein
levels decreased when MCF-7 cells were exposed to TNF-a
(Fig. 5). In NCI/ADR-RES, there were no significant
differences of PKC-a, -u and -~ levels in cells treated with
leptin, glucose, and TNF-a (Fig. 5). These results suggested
that PKC-a may be involved in the regulation of leptin- and
glucose-induced cell proliferation in MCF-7 cells.
3.5. Effects of leptin and glucose on the expression of
nuclear hormone receptors (PPARa, g) in MCF-7
PPARg is expressed in human breast cancer cells and has
an important role in cell growth [29]. We examined possible
changes in PPARg and PPARa levels in cells treated with
leptin and glucose. As shown in Fig. 6, in MCF-7 cells,
leptin and glucose increased PPARg and PPARa levels,
whereas TNF-a decreased their expression. However, there
was no significant effect on PPARg or PPARa levels in
NCI/ADR-RES cells treated with leptin, glucose, or TNF-a.
4. Discussion
Based on epidemiological studies [1,2,7,8], obesity and
plasma leptin levels are risk factors in breast cancer, since
plasma leptin levels are higher in breast cancer patients
than control subjects. Leptin is implicated in the regu-
lation of food intake and energy balance. Leptin is also a
regulatory signal for a variety of other physiological pro-
cesses in addition to body weight maintenance [3]. How-
ever, the function of leptin appears to be more complex
because several non-adipose sources of leptin have been
reported [4–6]. Recently, leptin mRNA and protein have
been reported in breast cancer cell lines [9]. In this study,
we indicated that leptin increased cell proliferation
through cell cycle progression in MCF-7 breast cancer
cells, but not in multidrug-resistant NCI/ADR-RES cells
as shown by measurement of cell proliferation, DNA
synthesis, and cdk2/cyclin D1 expression. Cdk2 and
cyclin D1 may have also important roles in neoplastic
transformation and cell cycle progression through the
G1–S border. Ectopic ex- pression of cyclin D1 contrib-
utes to the oncogenic transformation of cells [15,16], and
cyclin D1 overexpression in the mammary gland of
transgenic mice induces mammary carcinoma [34]. Our
finding that leptin and high glucose induced up-regulation
of cdk2 and cyclin D1 indicates that MCF-7 cell prolif-
eration was activated through the alteration of cell check-
points that accelerate cell cycle progression. Since TNF-a
has an anti-mitogenic activity in MCF-7 cells through
suppression of cells in S phase [19], we examined TNF-a
effects on cell proliferation, cdk2, cyclin D1, and PPARg
expression. TNF-a significantly suppressed cell prolifer-
ation and expression for cdk2, cyclin D1, and PPARg as
demonstrated previously [19].
PKC levels were related to cell cycle progression in
earlier studies. We previously demonstrated that PKC-hII is
overexpressed in MCF-7/ADR cells and PKC-hII has an
important role in glucose-induced MCF-7 cell proliferation
[14]. PKC isozyme expression and subcellular distribution
are tissue-specific [23]. Our findings indicated that PKC-a
may have roles in leptin-induced cell proliferation in MCF-7
cells, in particular, at the cell cycle progression checkpoint
similar to cdk2 and cyclin D1. On the other hand, in NCI/
ADR-RES cells, glucose- and leptin-induced changes of
PKC isozymes were not observed. Increasing PKC-a levels
may have an important role for the regulation of cell
proliferation. PKC-a overexpression induces a more aggres-
sive [35] or more transformed [36] neoplastic phenotype in
MCF-7. We also have examined that overexpression of
PKC-a stimulated cell proliferation compared to wild-type
of MCF-7 cells (data not shown). These facts indicated that
PKC-a has a stimulatory role in the regulation of cell
proliferation in MCF-7 cells.
PPARs are lipid-activated transcription factors which
control the promoters of multiple genes encoding enzymes
in the lipid metabolic pathways [25–28]. In this study,
leptin and high glucose treatment increased PPARg and
PPARa in MCF-7 cells. However, in NCI/ADR-RES cells,
leptin and high glucose had no significant effects on
expression of these transcription factors. Up-regulation of
PPARg and PPARa may be a step for the acceleration of
cell proliferation in MCF-7 cells. Motomura et al. [37]
reported that PPARg was highly expressed in the nuclei of
pancreatic adenocarcinoma cells, whereas normal pancreatic
duct epithelial cells expressed no PPARg. Overexpression
of PPARg has an important association with carcinogenec-
ity, since increased expression of PPARg is reported in
colon adenocarcinoma [38], lung cancer [39], breast cancer
[40], and prostate cancer [41]. These facts indicate that up-
regulation of PPARg may have a molecular link with
increased risk of cancer. However, the relationship between
up-regulation of PPARs and function of PKC isozymes
should also be elucidated.
This is the first demonstration that leptin and high
glucose exposure increases MCF-7 cell proliferation. Our
findings that leptin and high glucose stimulate cell cycle
progression with up-regulation of PKC-a, PPARg and
PPARa may be relevant in terms of diabetes and obesity
as risk factors for breast cancer. Leptin- or glucose-induced
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changes in PKC-a levels may be characteristic of MCF-7
breast cancer cells.
Leptin and high glucose may contribute to increased rates
of cell cycle progression by increasing PPARg and PPARa
levels. Our findings that leptin and high glucose act through
PKC-amight provide further insight into the regulation of cell
proliferation in MCF-7 human breast cancer cells.
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